Time filter

Source Type

Chen B.,Chinese University of Hong Kong | Gu T.,U.S. Center for Disease Control and Prevention | Ma B.,Walvax Biotechnology | Zheng G.,Yunnan Guandu Prison | And 8 more authors.
Journal of Molecular Neuroscience | Year: 2014

Accumulating evidence suggests that the hypothalamic-pituitary-adrenal (HPA) axis might play a major role in genetic susceptibility of aggressive behavior. The aim of the present study is to investigate the association between corticotrophin-releasing hormone receptor 1 (CRHR1) gene and aggressive behavior in Chinese southwest Han population. Participants consist of 282 healthy controls and 177 violent criminals (including robbery and intentional injury, which represent for aggressive behavior towards property and aggressive behavior towards others). Three tag single nucleotide polymorphisms (SNPs) of CRHR1 gene including rs4458044, rs242924, and rs1768996 were genotyped using improved multiplex ligase detection reaction (iMLDR) methods. Single-locus analysis revealed that none of the studied SNPs was significantly associated with the risk of aggressive behavior; however, haplotype analysis showed that a haplotype GGA significantly increased the susceptibility of aggressive behavior towards others with an odds ratios equal to 3.32 (p = 0.003). The present results, for the first time, indicate that the CRHR1 gene polymorphism is significantly associated with aggressive behavior in Chinese southwest Han population. Subjects with GGA haplotype have an increased susceptibility to aggressive behavior towards others. © 2013 Springer Science+Business Media. Source

Tang L.,Changsha Medical University | Chen B.,Chinese University of Hong Kong | Ma B.,Walvax Biotechnology | Nie S.,Kunming Medical University
Genetics and Molecular Research | Year: 2014

In this study, we investigated the association between 5 interferon regulatory factor-5 (IRF5) single nucleotide polymorphisms (SNPs) and autoimmune diseases using the Medline citation index. Twenty-eight studies with 74 comparisons, including 16 rheumatoid arthritis (RA), 43 systemic lupus erythematous (SLE), 2 juvenile idiopathic arthritis (JIA), 6 multiple sclerosis (MS), and 5 systemic sclerosis (SSc) studies, were examined in the meta-analysis. The SNP rs2004640 was significantly associated with SLE, MS, and SSc, but not with JIA [odds ratio (OR) = 1.06, 95% confidence interval (CI) = 0.90-1.24, P = 0.48] or RA (OR = 1.03, 95%CI = 0.95-1.11, P = 0.44). A significant association was observed between rs2280714 and SLE, MS, and SSc, but not RA (OR = 1.01, 95%CI = 0.94-1.09, P = 0.80). Rs10954213 was associated with the pathogenesis of SLE, RA, MS, and SSc. rs2070197 and the exon 6 insertion were significantly associated with SLE. Haplotypes containing rs2004640T and rs2280714T were significantly associated with an increased risk of SLE, but not with RA. This meta-analysis certified that IRF5 polymorphisms confer susceptibility to SLE, MS, and SSc. To further confirm the correlations between polymorphisms of IRF5 and autoimmune disease susceptibility, studies involving a larger number of patients worldwide are necessary. © FUNPEC-RP. Source

Walvax Biotechnology | Date: 2012-03-20

Bacteriostats for medicinal, dental and veterinary use; Biocides; Biological tissue cultures for veterinary purposes; Chemical reagents for medical or veterinary purposes; Depuratives for the body; Dietetic foods adapted for medical purposes; Fillings for teeth; Pharmaceutical preparation for skin care; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for wounds; Pharmaceutical products for the prevention and treatment of cancer; Surgical tissues; Vaccines. Biological research; Chemical research; Design services for packaging; Dress design services; Material testing; Programming of computer software for others; Surveying; Technical research in the field of aeronautics; Weather forecasting.

NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by Walvax Biotechnology Co., Ltd (“Walvax”) (SZSE: 300142), a biopharmaceutical company in China. Walvax is harnessing the Medidata Clinical Cloud® platform to improve data management activities and drive biomedical innovation in the development of a pneumococcal conjugate vaccine for infants. “Pneumococcal infections—including pneumonia, blood infections and meningitis—can be extremely difficult to treat, making prevention through vaccination a critical component of patient care,” said Yi Zhang, Vice President, Walvax. “We’re pleased to be using Medidata’s robust, globally-validated technology to bring greater speed and operational efficiencies to our pneumococcal conjugate vaccine trials, ultimately leading to a safe and effective way to ensure young children are protected from the devastating effects of pneumococcal diseases.” Founded in 2001, Walvax Biotechnology specializes in the research, development, production and distribution of bio-medicine products, including vaccines and blood products. To optimize the execution of its novel research on a vaccine for pneumococcal conjugate (PCV13)—the first multi-center clinical trials to be conducted on infants and toddlers in China—Walvax is utilizing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®). The Chinese biopharmaceutical company is also leveraging training available through Medidata’s professional services offering to speed study implementation and ensure trial timelines are met. "Medidata's cloud-based platform is designed to bring efficiencies to clinical trials of all sizes and therapeutics areas," said Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region. "We’re proud to be collaborating with Walvax as the organization advances pneumococcal conjugate vaccine research in China, resulting in better preventative treatment for young people around the world." Walvax Biotechnology Co., Ltd. (“Walvax”) was founded in 2001, which is a modern biological pharmaceutical enterprise engaged in R & D, production and sales of bio-medicine products. Walvax is a National Validated High-tech Enterprise and Enterprise Technical Center. In November, 2010, Walvax Biotechnology Co., Ltd. (stock name: Walvax Biotech, and stock code: 300142) listed on Shenzhen Stock Exchange. Walvax is committed to provide safe bio-medicine (such as vaccines, blood products and so on) with excellent quality and advanced technology for domestic and foreign markets. Walvax’s headquarters is located in Kunming, Yunnan Province of China. Walvax has a staff of more than 1,200, and has a modern R&D center in National High-tech Zone of Kunming, and a modern vaccine production base and pilot base in High-tech Zone of Yunnan Yuxi and Jiangsu Taizhou China Medical City, respectively. Walvax’s marketing network covers 30 provinces and cities of China, which includes more than 2,000 counties. Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Discover hidden collaborations